Novartis’ asthma candidate beats GlaxoSmithKline’s in Phase 2 trial
Category: #health  By Pankaj Singh  Date: 2019-05-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis’ asthma candidate beats GlaxoSmithKline’s in Phase 2 trial
  • The clinical study linked Novartis’ QVM149 to significant lung function improvements.
  • If a Phase 3 trial confirms the results, Novartis intends to unveil the product in 2020.

Novartis International AG (Novartis), a renowned Swiss multinational pharmaceutical firm, has reportedly announced that its triple-combination asthma drug, QVM149 has defeated Advair, developed by British pharmaceutical firm, GlaxoSmithKline (GSK) in a Phase 2 clinical trial.

Reports cite, the clinical study linked Novartis’ QVM149 to statistically significant lung function improvements, which led the company to promote its potential to improve the outcomes of uncontrolled asthma.

According to reliable reports, Novartis’ QVM149 was compared with GSK’s Advair & placebo and results suggested that glycopyrronium bromide, indacaterol acetate and mometasone furoate; the triplets, when inhaled through the Breezhaler device performed substantially better in improving the patient’s lung function.

Novartis’ second clinical trial also assessed whether the triplets’ effects vary depending upon the time it was administered during the day. The assessment found that the triplet outperformed the placebo regardless of the time it was administered; the morning or the evening.

Advair’s initial success made it into a blockbuster product. Now, the drug faces generic competition, however, there is still scope for branded products that further improves on it to boost sales, which has led Novartis to endorse QVM149 as a potential billion-dollar drug.

Despite beating Advair, Novartis’ QVM149 would have to come through in its ongoing Phase 3 trials to properly deliver on its recent hype. Meanwhile, the Swiss pharmaceutical firm is fleshing out evidence to support the triplet using data from previous phase trials.

According to reports, given that the triplet’s safety & tolerability outcomes are clean, the company thinks that the clinical data places QVM149 a step closer to establishing itself as a once-daily asthma treatment option for approximately one-third of asthma patients that are being served poorly by existing therapies.

If the Phase 3 trial confirms the results, Novartis intends to unveil the product in 2020 and promote it as a blockbuster in the upcoming years.

Source Credit: https://www.fiercebiotech.com/biotech/novartis-asthma-triplet-beats-gsk-s-advair-phase-2-trial

https://endpts.com/novartis-drums-up-anticipation-for-blockbuster-to-be-with-phii-data-on-asthma-drug/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...